Accera Inc.
This article was originally published in Start Up
Executive Summary
Accera Inc. has a radically different theory about what causes Alzheimer's Disease. It ties the disease, and possibly its precursor mild cognitive impairment, to a decline in cerebral energy metabolism. The company's lead compounds are designed to address that shortfall.
You may also be interested in...
The Future of Memory Disorders
The market for products that boost memory and cognition is vast, and underserved. But until clinicians and companies define cognitive diseases and develop clinical models for them, start-ups developing memory drugs face an uncertain future. Included in this feature are profiles of Accera Inc., GBtherapeutics Ltd., Saegis Pharmaceuticals Inc. and Sention Inc.
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.